APIMEDS PHARMACEUTICALS US INC Financials
This page shows APIMEDS PHARMACEUTICALS US INC (APUS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Apimeds' filings point to a funding-dependent business that shifted into acute balance-sheet strain as cash nearly disappeared.
Between FY2023 and FY2024, cash fell from$410K to$3K , leaving almost no liquid buffer for routine obligations. That erosion coincided with negative equity of-$1.36M in FY2024, showing the business is now supported more by obligations than by its recorded asset base.
FY2023 already looked externally financed: operating cash burn was
The short-term posture deteriorated sharply. Current assets were just
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of APIMEDS PHARMACEUTICALS US INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
APIMEDS PHARMACEUTICALS US INC carries a low D/E ratio of 0.07, meaning only $0.07 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
APIMEDS PHARMACEUTICALS US INC's current ratio of 1.31 is below the typical benchmark, resulting in a score of 21/100. This tight liquidity could limit financial flexibility if cash inflows slow.
APIMEDS PHARMACEUTICALS US INC generates a -3.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
APIMEDS PHARMACEUTICALS US INC passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, APIMEDS PHARMACEUTICALS US INC generates $1.49 in operating cash flow (-$8.9M OCF vs -$6.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
APIMEDS PHARMACEUTICALS US INC earns $-42.1 in operating income for every $1 of interest expense (-$11.9M vs $283K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
APIMEDS PHARMACEUTICALS US INC's EBITDA was -$11.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
APIMEDS PHARMACEUTICALS US INC reported -$6.0M in net income in fiscal year 2025.
APIMEDS PHARMACEUTICALS US INC earned $-0.55 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 205.6% from the prior year.
Cash & Balance Sheet
APIMEDS PHARMACEUTICALS US INC generated -$9.0M in free cash flow in fiscal year 2025, representing cash available after capex.
APIMEDS PHARMACEUTICALS US INC held $1.6M in cash against $0 in long-term debt as of fiscal year 2025.
APIMEDS PHARMACEUTICALS US INC had 13M shares outstanding in fiscal year 2025. This represents an increase of 59.1% from the prior year.
Margins & Returns
APIMEDS PHARMACEUTICALS US INC's ROE was -3.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
APIMEDS PHARMACEUTICALS US INC invested $1.6M in research and development in fiscal year 2025.
APIMEDS PHARMACEUTICALS US INC invested $57K in capex in fiscal year 2025, funding long-term assets and infrastructure.
APUS Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $620K-4.9% | $652K | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | $1.2M-39.1% | $2.0M+452.2% | $364K | N/A | $300K-29.9% | $428K+57.4% | $272K |
| Operating Income | N/A | -$1.8M+30.8% | -$2.7M-631.1% | -$364K | N/A | -$300K+29.9% | -$428K-57.4% | -$272K |
| Interest Expense | N/A | $6K+104.4% | $3K-91.9% | $38K | N/A | $33K+47.5% | $22K-17.8% | $27K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$1.8M+33.1% | -$2.7M-561.6% | -$402K | N/A | -$333K+26.0% | -$449K-51.6% | -$296K |
| EPS (Diluted) | N/A | $-0.14+46.2% | $-0.26-420.0% | $-0.05 | N/A | $-0.04+33.3% | $-0.06-50.0% | $-0.04 |
APUS Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $164.2M+1675.0% | $9.3M-12.3% | $10.5M+3957.9% | $260K+1890.5% | $13K | N/A | N/A | N/A |
| Current Assets | $14.0M+53.9% | $9.1M-12.2% | $10.3M+3882.1% | $260K+1890.5% | $13K | N/A | N/A | N/A |
| Cash & Equivalents | $1.6M-76.6% | $7.0M-20.0% | $8.7M+3389.4% | $250K+7145.8% | $3K-87.0% | $27K-58.0% | $63K-57.0% | $147K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $10.8M+894.7% | $1.1M+34.7% | $809K-60.0% | $2.0M+47.3% | $1.4M | N/A | N/A | N/A |
| Current Liabilities | $10.7M+882.8% | $1.1M+34.7% | $809K-54.3% | $1.8M+72.8% | $1.0M | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $153.3M+1779.1% | $8.2M-16.2% | $9.7M+653.1% | -$1.8M-29.6% | -$1.4M-29.8% | -$1.0M-46.6% | -$714K-169.8% | -$265K |
| Retained Earnings | -$10.4M-12.5% | -$9.2M-23.9% | -$7.5M-55.5% | -$4.8M-9.2% | -$4.4M | N/A | N/A | N/A |
APUS Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.8M-121.2% | -$1.7M+48.6% | -$3.4M-16446.5% | -$20K | N/A | -$187K-1.5% | -$184K+30.0% | -$263K |
| Capital Expenditures | $21K-5.0% | $23K | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$3.8M-119.6% | -$1.7M | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$10.0M-44374.0% | -$23K | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $8.5M | $0-100.0% | $11.9M+4338.4% | $267K | N/A | $150K | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
APUS Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -21.8%+5.5pp | -27.3% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | -19.3%+6.0pp | -25.2%+129.6pp | -154.8% | N/A | N/A | N/A | N/A |
| Current Ratio | 1.31-7.0 | 8.34-4.5 | 12.79+12.6 | 0.15+0.1 | 0.01 | N/A | N/A | N/A |
| Debt-to-Equity | 0.07-0.1 | 0.13+0.1 | 0.08+1.2 | -1.15-0.1 | -1.01 | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is APIMEDS PHARMACEUTICALS US INC profitable?
No, APIMEDS PHARMACEUTICALS US INC (APUS) reported a net income of -$6.0M in fiscal year 2025.
What is APIMEDS PHARMACEUTICALS US INC's EBITDA?
APIMEDS PHARMACEUTICALS US INC (APUS) had EBITDA of -$11.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is APIMEDS PHARMACEUTICALS US INC's return on equity (ROE)?
APIMEDS PHARMACEUTICALS US INC (APUS) has a return on equity of -3.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is APIMEDS PHARMACEUTICALS US INC's free cash flow?
APIMEDS PHARMACEUTICALS US INC (APUS) generated -$9.0M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is APIMEDS PHARMACEUTICALS US INC's operating cash flow?
APIMEDS PHARMACEUTICALS US INC (APUS) generated -$8.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are APIMEDS PHARMACEUTICALS US INC's total assets?
APIMEDS PHARMACEUTICALS US INC (APUS) had $164.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are APIMEDS PHARMACEUTICALS US INC's capital expenditures?
APIMEDS PHARMACEUTICALS US INC (APUS) invested $57K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does APIMEDS PHARMACEUTICALS US INC spend on research and development?
APIMEDS PHARMACEUTICALS US INC (APUS) invested $1.6M in research and development during fiscal year 2025.
What is APIMEDS PHARMACEUTICALS US INC's current ratio?
APIMEDS PHARMACEUTICALS US INC (APUS) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.
What is APIMEDS PHARMACEUTICALS US INC's debt-to-equity ratio?
APIMEDS PHARMACEUTICALS US INC (APUS) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is APIMEDS PHARMACEUTICALS US INC's return on assets (ROA)?
APIMEDS PHARMACEUTICALS US INC (APUS) had a return on assets of -3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is APIMEDS PHARMACEUTICALS US INC's cash runway?
Based on fiscal year 2025 data, APIMEDS PHARMACEUTICALS US INC (APUS) had $1.6M in cash against an annual operating cash burn of $8.9M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is APIMEDS PHARMACEUTICALS US INC's Piotroski F-Score?
APIMEDS PHARMACEUTICALS US INC (APUS) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are APIMEDS PHARMACEUTICALS US INC's earnings high quality?
APIMEDS PHARMACEUTICALS US INC (APUS) has an earnings quality ratio of 1.49x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can APIMEDS PHARMACEUTICALS US INC cover its interest payments?
APIMEDS PHARMACEUTICALS US INC (APUS) has an interest coverage ratio of -42.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is APIMEDS PHARMACEUTICALS US INC?
APIMEDS PHARMACEUTICALS US INC (APUS) scores 20 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.